Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.79 USD
Change Today +0.04 / 0.41%
Volume 18.9K
CGIX On Other Exchanges
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $12.75
52 Week Low
12/3/14 - $4.83
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. The company offers microarray based testing, a microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer; and next generation sequencing testing, a proprietary next generation sequencing tests for the diagnosis and prognosis of genomic alterations in chronic lymphocytic leukemia, myeloma, and B-cell non-hodgkin's lymphomas. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutation analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides fluorescent in situ hybridization testing, an analysis of abnormalities at the chromosomal and gene levels; histology testing, a microscopic examination of stained tissue sections; and cytology testing, a non-gynecological fluid preparation for microscopic evaluations. Further, it offers IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various oncology-focused tests and laboratory services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. It also provides Expand Dx program for community hospital’s oncology diagnostic process; and consulting, guidance, and preparation of samples and clinical trial design. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

139 Employees
Last Reported Date: 03/16/15
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $260.3K
Vice President of Research & Development
Total Annual Compensation: $297.9K
Compensation as of Fiscal Year 2014.

cancer genetics inc (CGIX) Key Developments

Cancer Genetics, Inc. Presents at 2015 Sidoti Emerging Growth Conference, Sep-02-2015 10:00 AM

Cancer Genetics, Inc. Presents at 2015 Sidoti Emerging Growth Conference, Sep-02-2015 10:00 AM. Venue: Marriott Marquis in Times Square, New York, New York, United States. Speakers: Panna Sharma, Chief Executive Officer, President and Director.

Cancer Genetics, Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015

Cancer Genetics, Inc. reported unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, revenue increased 177% to $4.2 million from $1.5 million for the three months ended June 30, 2014, as a result of an increase of $1.2 million in organic growth across the Biopharma and Clinical businesses and the contribution of $1.5 million in revenue from acquisitions. Loss from operations was $4,413,801 against $4,411,117 a year ago. Loss before income taxes was $4,979,843 against $4,186,704 a year ago. Net loss was $4,979,843 or $0.51 per basic and diluted share against $4,186,704 or $0.47 per diluted share a year ago. For the six months, revenues increased 191% to $8.6 million from $2.9 million for the six-months ended June 30, 2014, as a result of a $2.1 million increase in existing CGI business and $3.6 million in revenue contribution from acquisitions. Loss from operations was $8,565,845 against $8,347,958 a year ago. Loss before income taxes was $9,258,150 against $8,486,538 a year ago. Net loss was $9,258,150 or $0.95 per basic and diluted share against $6,672,597 or $0.74 per diluted share a year ago. Net cash used in operating activities was $7,359,855 against $5,812,880 a year ago. Purchase of fixed assets was $257,507 against $385,151 a year ago.

Cancer Genetics, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Cancer Genetics, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 11, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $9.79 USD +0.04

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $23.70 USD +0.05
Genomic Health Inc $25.66 USD -0.67
Myriad Genetics Inc $38.00 USD -0.82
NeoGenomics Inc $6.29 USD -0.19
Rosetta Genomics Ltd $2.47 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation CGIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at